| P2093 | author name string | Tan C | |
| | Hendifar A | |
| | Osipov A | |
| | Tuli R | |
| | Yaffee P | |
| P2860 | cites work | Postoperative adjuvant chemotherapy in rectal cancer operated for cure | Q24201072 |
| | Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer | Q27851407 |
| | Cetuximab for the treatment of colorectal cancer. | Q27851419 |
| | K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 |
| | Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 |
| | Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 |
| | Cancer statistics, 2014 | Q27861018 |
| | Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 |
| | FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study | Q28189472 |
| | Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab | Q28219257 |
| | Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 |
| | Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan | Q28249001 |
| | Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 |
| | Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 |
| | Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer | Q28308193 |
| | Irinotecan pathway genotype analysis to predict pharmacokinetics | Q28611372 |
| | Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 |
| | Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status | Q29619648 |
| | Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study | Q29619653 |
| | Impact of body-size measures on irinotecan clearance: alternative dosing recommendations | Q33183241 |
| | The Role of UGT1A1*28 Polymorphism in the Pharmacodynamics and Pharmacokinetics of Irinotecan in Patients With Metastatic Colorectal Cancer | Q60697890 |
| | Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01 | Q68125681 |
| | NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer | Q68536918 |
| | Prolongation of the disease-free interval in surgically treated rectal carcinoma | Q69861242 |
| | Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours | Q73158891 |
| | Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients | Q73648001 |
| | Synergistic activity of oxaliplatin and 5-fluorouracil in patients with metastatic colorectal cancer with progressive disease while on or after 5-fluorouracil | Q74648273 |
| | Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model | Q77555291 |
| | Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group | Q80428523 |
| | Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer | Q80455371 |
| | High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history | Q80807881 |
| | Capecitabine plus 3-weekly irinotecan (XELIRI regimen) as first-line chemotherapy for metastatic colorectal cancer: phase II trial results | Q80971779 |
| | Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate | Q81084956 |
| | Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study | Q81311015 |
| | Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE) | Q82294729 |
| | Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes | Q82656539 |
| | Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study | Q83801480 |
| | Dosing strategies for anticancer drugs: the good, the bad and body-surface area | Q33184074 |
| | Oxaliplatin-related side effects: characteristics and management | Q33345201 |
| | Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale | Q33366660 |
| | Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials | Q33382045 |
| | Clinical features of hypersensitivity reactions to oxaliplatin: a 10-year experience | Q33382153 |
| | Effective surgical adjuvant therapy for high-risk rectal carcinoma | Q33387384 |
| | Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis | Q33558693 |
| | Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials | Q33795896 |
| | Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors | Q33828690 |
| | Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 |
| | Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial | Q33922925 |
| | Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures | Q33962340 |
| | Bevacizumab increases risk for severe proteinuria in cancer patients | Q34124173 |
| | Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin | Q34212131 |
| | A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 |
| | Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group | Q34511070 |
| | Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study | Q34514696 |
| | Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial | Q34555503 |
| | Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study | Q34583973 |
| | Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 |
| | Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer | Q34624378 |
| | Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologi | Q34624438 |
| | Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis | Q34626720 |
| | Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial | Q34629442 |
| | Enhancement of the antitumor effects of 5-fluorouracil by folinic acid | Q34632688 |
| | Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial | Q34637479 |
| | Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years | Q34637749 |
| | Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial | Q34638544 |
| | Survival outcomes of bevacizumab beyond progression in metastatic colorectal cancer patients treated in US community oncology | Q34638749 |
| | Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer | Q34644719 |
| | Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial | Q34645599 |
| | Multicentre phase II study of bifractionated CPT-11 with bimonthly leucovorin and 5-fluorouracil in patients with metastatic colorectal cancer pretreated with FOLFOX. | Q36695803 |
| | Capecitabine vs continuous infusion 5-FU in neoadjuvant treatment of rectal cancer. A retrospective review | Q36957572 |
| | Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis | Q37328873 |
| | Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review | Q37345974 |
| | Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. | Q37412279 |
| | Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials | Q37692420 |
| | Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis | Q37807240 |
| | Locally advanced rectal cancer: a comparison of management strategies | Q37895253 |
| | Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial | Q39394495 |
| | UGT1A1*28 polymorphism predicts irinotecan-induced severe toxicities without affecting treatment outcome and survival in patients with metastatic colorectal carcinoma | Q40426198 |
| | First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin | Q40580831 |
| | Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy | Q40659621 |
| | Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation | Q41314665 |
| | Mechanisms of topoisomerase I inhibition by anticancer drugs. | Q41315156 |
| | Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study | Q43281857 |
| | Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies | Q43559046 |
| | Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"? | Q43843440 |
| | Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. | Q44045712 |
| | A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer | Q44093928 |
| | Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction | Q44200284 |
| | Oxaliplatin | Q44751137 |
| | Bevacizumab in association with de Gramont 5-fluorouracil/folinic acid in patients with oxaliplatin-, irinotecan-, and cetuximab-refractory colorectal cancer: a single-center phase 2 trial. | Q44789015 |
| | Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment | Q44820379 |
| | Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis | Q45057200 |
| | Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer | Q45091068 |
| | Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741. | Q45095320 |
| | Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer | Q45166759 |
| | UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan | Q45263765 |
| | Shorter bevacizumab infusions do not increase the incidence of proteinuria and hypertension | Q46062890 |
| | Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study. | Q46157402 |
| | Management of allergic reactions to oxaliplatin in colorectal cancer patients. | Q46159860 |
| | Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study | Q46473453 |
| | Phase III study of weekly high-dose infusional fluorouracil plus folinic acid with or without irinotecan in patients with metastatic colorectal cancer: European Organisation for Research and Treatment of Cancer Gastrointestinal Group Study 40986. | Q46531455 |
| | Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study | Q46542857 |
| | EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer | Q46662707 |
| | Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study | Q46781981 |
| | EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. | Q47793744 |
| | Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial. | Q51776004 |
| | Frequency of KRAS, BRAF, and NRAS mutations in colorectal cancer. | Q54614277 |
| | Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. | Q55067760 |
| | Capecitabine plus oxaliplatin (xelox) versus protracted 5-fluorouracil venous infusion plus oxaliplatin (pvifox) as first-line treatment in advanced colorectal cancer: a GOAM phase II randomised study (FOCA trial) | Q56996728 |
| | Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study | Q57152185 |
| | Relationship of Hepatic Functional Imaging to Irinotecan Pharmacokinetics and Genetic Parameters of Drug Elimination | Q57758941 |
| | UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan | Q58408313 |
| | Phase III Study of Capecitabine Plus Oxaliplatin Compared With Continuous-Infusion Fluorouracil Plus Oxaliplatin As First-Line Therapy in Metastatic Colorectal Cancer: Final Report of the Spanish Cooperative Group for the Treatment of Digestive Tumor | Q58614884 |
| | Sequential versus combination chemotherapy for the treatment of advanced colorectal cancer (FFCD 2000–05): an open-label, randomised, phase 3 trial | Q60629643 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 185-200 | |
| P577 | publication date | 2015-04-01 | |
| P1433 | published in | Journal of gastrointestinal oncology | Q26842467 |
| P1476 | title | Review of systemic therapies for locally advanced and metastatic rectal cancer | |
| P478 | volume | 6 | |